Chinese biotech company Jacobio Pharma announced on Monday that it had received approval from Chinese regulatory authorities for the registration phase-3 clinical trial of a combination therapy using its SHP2 inhibitor drug candidate JAB-3312.
SHP2 inhibitors are expected worldwide to have a substantial clinical effect in cancer and immunity disease treatment, and the approval made JAB-3312 the first SHP2 inhibitor to enter the phase-3 clinical study globally.
The approved clinical study in China is designed to evaluate the efficacy and safety of JAB-3312 in combination with the company's other investigational drug candidate KRAS G12C inhibitor glecirasib, for treating first-line non-small cell lung cancer patients with KRAS G12C mutations.
The control arm is the current standard treatment for first-line non-small cell lung cancer, which is the combination therapy of PD-1 antibody and chemotherapy.
Related articles:
Related suggestion:
Iran's hardliners employ female 'hijab enforcers' to spy on bareRays starter Ryan Pepiot departs with leg bruise after getting hit by 107.5 mph line driveBritain 'must lay out red carpet' to retain top tech firmsIt started with a tweet. What if Harry Potter attended an HBCU? Now it's a book seriesFloods in southern Brazil kill at least 60, with 101 people missingCelta Vigo closer to avoiding relegation after edging Villarreal in Spanish leagueOrbán challenger in Hungary mobilizes thousands at a rare demonstration in a government strongholdEMILY PRESCOTT: It's a power meeting! Eco Ellie Goulding's cosy chat with Ovo energy bossPSV Eindhoven wraps up its 25th Dutch Eredivisie title by beating Sparta Rotterdam 4Bob Avellini, quarterback who teamed with Walter Payton to lead Bears to 1977 playoffs, dies at 70
2.131s , 6498.078125 kb
Copyright © 2024 Powered by Chinese inhibitor drug candidate becomes first to enter phase ,Stellar Spectacle news portal